Ivosidenib for glioblastoma uopdate 2023
Ivosidenib, sold under the brand name Tibsovo, is an anti-cancer medication for the treatment of acute myeloid leukemia and cholangiocarcinoma. It is a small molecule inhibitor of isocitrate dehydrogenase-1, which is mutated in several forms of cancer. Despite the significance of IDH1/2 mutations, however, there are no FDA-approved IDH inhibitors for brain cancer. Ivosidenib (Tibsovo), an IDH1 inhibitor, is indicated for IDH1-mutant acute myeloid leukemia (AML) in newly diagnosed patients who are 75 years or older or have comorbidities that preclude intensive chemotherapy and for patients with relapsed AML, as well as for patients with previously treated IDH1-mutant locally advanced or metastatic cholangiocarcinoma. There are no guidelines or randomized studies to support its use.
Wangqi Tian et al, Recent advances of IDH1 mutant inhibitor in cancer therapy. Front. Pharmacol., 24 August 2022